Loading patent…
OwnerLawrence J. Thomas, Angelo Scorpio +1inventors
InventorsLawrence J. Thomas, Angelo Scorpio, David T. Beattie
Estimating the term…
Methods are disclosed for immunizing a mammal against B. anthracis using a composition of pure recombinant Protective Antigen (rPA), optionally in combination with truncated Lethal Factor polypeptide (LFn). Formulations of the pure rPA immunogen have little or no reactogenicity and therefore may be administered to a mammalian subject in very high doses of 50 μg to 1000 μg or more rPA, which is at least four times the amount of PA included per dose in conventional anthrax vaccines. Preferred immunogenic compositions are free of adjuvant and other undesired components, further enhancing the effectiveness and safety of the compositions. Methods for preparing the immunogenic compositions and for purifying rPA and LFn polypeptides also are disclosed.
An immunogenic composition capable of raising an anti-B. anthracis antigen immune response in a mammal consisting essentially of recombinant B. anthracis Protective Antigen (rPA).
An immunogenic composition capable of raising an anti-B. anthracis antigen immune response in a mammal consisting essentially of rPA and a truncated, non-toxic B. anthracis Lethal Factor (LFn).
A method for eliciting an immune response in a mammalian subject against a B. anthracis antigen comprising:
A method of immunizing a mammalian subject against B. anthracis comprising:
A method for obtaining high-purity rPA which comprises:
A method for obtaining high-purity recombinant LFn polypeptide which comprises:
Use of pure recombinant PA in a vaccine regimen of up to four doses of 50 μg recombinant PA or more, to induce protective immunity to B. anthracis infection.
Dependencies are inferred from the claim text.